<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067833</url>
  </required_header>
  <id_info>
    <org_study_id>CJO-201</org_study_id>
    <nct_id>NCT01067833</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Oral K201 for Prevention of AF Recurrence</brief_title>
  <acronym>ARCTIC-AF</acronym>
  <official_title>A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary EffiCacy Study of K201 Oral for the Prevention of ATrial FIbrillation (AF) Recurrence in Subjects Post-Conversion From AF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequel Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequel Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, efficacy, and tolerability of 3 doses of K201 (oral) administered for
      up to 28 days in subjects with recent DC cardioversion to sinus rhythm from sustained
      symptomatic atrial fibrillation (AF duration &gt;3 days and &lt;6 months).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to first documented recurrence of symptomatic AF</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to first documented recurrence of symptomatic or asymptomatic AF</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>proportion of subjects in sinus rhythm</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of AF beats</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time in AF</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>safety assessments: vital signs, laboratory assays, ECG parameters, physical exams, frequency of adverse events</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K201</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K201</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K201</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K201 Tablet</intervention_name>
    <description>oral tablet, x28 days</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>oral tablet, x28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic AF (sustained &gt;3 days and &lt;6 months) and clinically indicated for
             cardioversion;

          -  Adequate anticoagulant therapy for cardioversion in accordance with standard practice
             as recommended by ACC/AHA/ESC guidelines or with local clinical practice;

          -  Hemodynamically stable (90 mmHg &lt; systolic blood pressure &lt; 190 mmHg)at screening and
             on Day 1;

        Exclusion Criteria:

          -  Known prolonged QT syndrome or QTc interval of &gt;0.500 sec at screening; familial long
             QT syndrome; previous Torsade de Pointes; ventricular fibrillation; or sustained
             ventricular tachycardia (VT);

          -  QRS &gt;0.130 sec;

          -  Previous episodes of second- or third-degree atrioventricular block;

          -  Unsuccessful DC cardioversion attempt within 3 months; prior ablation for AF;

          -  Persistent bradycardia with ventricular rate below 50 beats/min, sick-sinus syndrome
             or pacemaker (including CRT, AICD);

          -  Myocardial infarction (MI), cardiac surgery, angioplasty, unstable angina or acute
             coronary syndrome within 30 days prior to entry into the study;

          -  NYHA Class III or Class IV heart failure (HF) at screening or admission, or
             hospitalized for HF in previous 6 months;

          -  Known concurrent temporary secondary causes of AF;

          -  Received a Class I or Class III antiarrhythmic agent (including sotalol) within 5
             half-lives of randomization or amiodarone or dronedarone within 4 weeks;

          -  Received treatment with other drugs known to prolong the QT interval within 5
             half-lives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Chamberlin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sequel Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Howard C. Dittrich, CMO</name_title>
    <organization>Sequel Pharmaceuticals, Inc</organization>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>AF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

